The threat of increasing competition for GW Pharmaceuticals’ promising epilepsy drug took a toll on investors’ confidence last month.
Tag Archives: S&P Global Market Intelligence.
Why This Marijuana Stock Fell 16.4% in March
Insys Therapeutics dropped after it received disappointing news from the DEA regarding its marijuana drug Syndros.
What Caused This Marijuana Stock to Soar 27% in February?
Insys Therapeutics announced a compassionate-use program for its cannabis-based epilepsy drug, igniting optimism that the company is continuing to develop marijuana medicine.